Farmas USA

a mi lo que me escama es que nunca hay pre y hoy sí. poco volumen de capitalización.
no digo que no pueda ser.

suerte y stop de seguridad.
appy

Buen pre market parz ROSG +16%

1000 clsn a la saca.

20k a 1,60 tb a la saca
CLSN

menuda maniobra roba-carteras!

CLSN

DMC Recommends ImmunoCellular Therapeutics To Continue ICT-107 Phase II Trial

RELATED NEWS
ImmunoCellular Therapeutics Q1 13 Earnings Conference Call At 5:00 PM ET
ImmunoCellular To Present At Future Leaders Conference ; Webcast At 11:00 AM ET
ImmunoCellular Therapeutics To Present At ROTH Conference; Webcast At 4:30 PM ET
Trade IMUC now with
6/7/2013 6:33 AM ET
ImmunoCellular Therapeutics, Ltd. (IMUC: Quote) announced that the Data Monitoring Committee or DMC has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.

The company said the trial design for the ICT-107 study provides for the interim analysis to be conducted by the independent DMC after 32 events (patient deaths) are reached. ImmunoCellular remains blinded to the actual results and details of the interim analysis and any patient data pertaining to the ongoing trial. No additional interim analyses are planned. The company anticipates that the phase II trial should be completed by the end of 2013.

According to the company, the ICT-107 phase II trial is a randomized, placebo-controlled, double-blind study of ICT-107, a 6-antigen dendritic cell vaccine targeting glioblastoma tumor and cancer stem cell antigens, as a potential treatment for patients with newly diagnosed glioblastoma. The phase II trial has been fully enrolled, and a total of 124 patients have been randomized at 25 clinical trial sites in the US.

The trial utilizes a one-third, two thirds design: one third of the patients are treated with placebo, which is their own dendritic cells not exposed to antigen, and the treatment arm includes two thirds or about 80 patients who receive the ICT-107 vaccine. The regimen is four induction doses after radiation and chemotherapy, and then maintenance doses until the patient relapses. The primary endpoint of the trial is overall survival (OS). Secondary endpoints include progression-free survival (PFS), OS and PFS at various time intervals, immune response (T cells) and safety.

JAJA no mejor búscame uno tú para cuando el tiempo ocioso supere al productivo. Puta crisis!

En realidad yo llevo un año y medio igual, pero ahora me ha venido todo el curro junto. De todas formas, me parece que ya hemos encontrado ese trabajo. ¿Tú a qué te dedicas si se puede preguntar?